CVS Health has agreed to sell and issue about $4 billion in notes. The healthcare giant entered into an underwriting agreement with Barclays, J.P. Morgan Securities and Wells Fargo Securities on Aug.

CVS Health ( ($CVS) ) has shared an announcement. On August 11, 2025, CVS Health Corporation entered into an Underwriting Agreement to issue and ...

Fintel reports that on August 14, 2025, Baird upgraded their outlook for CVS Health (NYSE:CVS) from Neutral to Outperform.

While competitors continue to struggle with healthcare costs, Aetna and CVS are celebrating an 8.4% increase in ...

CVS Health said it plans to allocate $20 billion over the next decade to streamline the US health system. The initiative aims ...

This effort, announced at a “Make Health Tech Great Again” event at the White House, is focused on laying the foundation for ...

CVS, JNJ, and Tenet Healthcare shine as defensive picks with strong earnings momentum and attractive valuations.

CVS beat Wall Street estimates in its second quarter earnings Thursday, bringing relief to a stock under pressure from higher costs.

Through the power of strategic, well-built partnerships, CVS Health helps employees earn degrees — and at no cost to them.

It’s time for a wellness check at CVS Health. Shares of the company are down more than 20% this year as it grapples with higher-than-expected medical costs in its insurance unit and pharmacy ...

CVS Joins Race to Sell Cheaper, 'Biosimilar' Drugs Early next year, the chain will start producing a cheaper version of Humira, with other meds to follow. Here's what to know about biosimilar drugs.

CVS Health CVS 0.0% (NYSE: CVS) reported its Q3 results earlier this month, with revenues and earnings beating the street estimates, and we believe that CVS stock is undervalued, as discussed below.